1. 科研项目情况（部分）：

1)   国家自然科学基金面上项目，82170591, 脂肪来源sMCAM上调肝细胞膜受体型MCAM促进非酒精性脂肪性肝病的作用及机制研究，2022/1-2025/12，55万元，在研，主持

2)   国家自然科学基金青年基金项目，81500439，NS2TP在非酒精性脂肪性肝病中保护线粒体功能的机制研究，2016/1-2018/12，18万元，已结题，主持

3)   北京市自然科学基金面上项目, 7222097, 脂肪来源sMCAM通过氧化呼吸链对非酒精性脂肪性肝病炎症微环境的调控及机制, 2022/1-2024/12, 20万，在研，主持

4)   北京市医管局消化内科学科协同发展中心重点项目子课题，XXZ0401，孕晚期母婴阻断患者产后优化停药方案研究，2018/6-2022/12，34万，在研，主持

5)   首都卫生发展科研专项项目，首发2020-1-3051，粒细胞集落刺激因子提高肝衰竭生存率及疗效影响因素多中心临床研究, 2020/6-2023/5, 在研, 分课题负责人

6)   首都医科大学基础-临床科研合作基金，转录因子CHCHD2在非酒精性脂肪肝中的作用研究，2015/3-2017/3，5万，已结题，主持

7) 首都医学发展科研基金，2009-3152，肝细胞癌特异细胞蛋白标志物的筛选及其在肝癌早期诊断中的应用，2010/8-2012/12，6万元，已结题，主持

8) 北京市卫生局、中医管理局青年科学研究项目，QN2008-009，血RASSF1A和GSTP1基因启动子甲基化检测在HBV相关HCC诊断中的应用，2009/1-2010/12，4万元，已结题，主持

2. 人才项目情况：

1)   北京市医管局“青苗”人才培养计划, QML20161801，非酒精性肝病中CHCHD2结合代谢酶CYP2E1的作用及初步机制研究, 2017/1-2018/12, 12万，已结题，主持

2)   北京市留学人员科技活动择优资助项目，HCV core-SREBP2-HMGCR新途径及调控机制研究，2014年度，5万元，已结题，主持

3)   北京市优秀人才培养资助项目，2011D003034000028，乙型肝炎病毒对抑癌基因RUNX3表达的影响及其机制研究，2012/1-2013/12，5万元，已结题，主持

1)  Yue Li#, WenjingXiu#, Jingwen Xu, Xiangmei Chen, Guangyan Wang, Jinjie Duan, Lei Sun, Ben Liu,Wen Xie, Guangyin Pu, Qi Wang(王琦)*, ChunjiongWang*.Increased CHCHD2 expression promotes liver fibrosis in non-alcoholicsteatohepatitis via Notch/osteopontin signaling. JCIinsight.2022,7(23): e162402. (Q1, IF:9.496)

2）Qi Wang(王琦)#, Hong Zhao#, You Deng#, Huanwei Zheng, Huiling Xiang, Yuemin Nan, Jinhua Hu, Qinghua Meng, Xiaoyuan Xu, Jilian Fang, Jie Xu, Xiaoming Wang, Hong You, Calvin Q. Pan, Wen Xie*, Jidong Jia*. Validationof Baveno VII criteria for recompensation in entecavir-treated hepatitis Bpatients with decompensated cirrhosis. Journal of Hepatology.2022,77:1564-1572. (Q1, IF:30.083.)

3)   Li Y#, Yuan SL#,Yin JY, Yang K, Zhou XG, Xie W*, Wang Q(王琦)*. Differences of core genes inliver fibrosis and hepatocellular carcinoma: Evidence from integratedbioinformatics and immunohistochemical analysis. World Journal ofGastrointestinal Oncology. 2022, 14(7): 1265- 1280.

4)   Shouli Yuan#,Meng Dong#, Hanlin Zhang#, Hongde Xu#, QiWang(王琦)#, Chunlong Yan,Rongcai Ye, Xiaoxiao Jiang, Huiqiao Zhou, Li Chen, Jun Cheng*, Wen Xie*, WanzhuJin*. Oral delivery of a Lactococcus lactis expressing extracellular TGFβR2alleviates hepatic fibrosis. Applied Microbiology and Biotechnology.2021,105(14-15):6007-6018.

5)   Qi Wang(王琦)#, Wen Xie#,Ligai Liu, Peng Wang, Calvin Q Pan. Serum markers for predicting advancedfibrosis in patients with chronic hepatitis B and nonalcoholic fatty liverdisease. Medicine. 2021, 100 (18) :e25327.

6)   Pengcheng Du#,Nan Ding#, Jiarui Li#, Fujie Zhang#, QiWang(王琦)#, Zhihai Chen#,Chuan Song, Kai Han, Wen Xie, Jingyuan Liu, Linghang Wang, Lirong Wei, ShanfangMa, Mingxi Hua, Fengting Yu, Lin Wang, Wei Wang, Kang An, Jianjun Chen, HaizhouLiu, Guiju Gao, Sa Wang, Yanyi Huang, Angela R Wu, Jianbin Wang*, Di Liu*, HuiZeng*, Chen Chen*. Genomic surveillance of COVID-19 cases in Beijing. Nature communications. 2020,11:5503.

7)   Qi Wang(王琦), Hong Zhao,Ligai Liu, Yanbin Wang, Ting Zhang, Minghui Li, Yanli Xu, Guiju Gao, HaofengXiong, Ying Fan, Ying Cao, Rui Ding, Jingjing Wang, Cheng Cheng, Wen Xie. Patternof liver injury in adult patients with COVID-19: a retrospective analysis of105 patients. Military Medical Research. 2020,7(1):28.

8)   Chen Chen#,Guiju Gao#, Yanli Xu#, Lin Pu#, Qi Wang(王琦)#, Liming Wang#,Wenling Wang, Yangzi Song, Meiling Chen, Linghang Wang, Fengting Yu, Siyuan Yang,Yunxia Tang, Li Zhao, Huijuan Wang, Yajie Wang, Hui Zeng*, Fujie Zhang*.SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal Samples inPatients With COVID-19. Annals of Internal Medicine. 2020,172(12):832-834.

9)   Yue Li, XiaoyanCheng, Changlan Chen, Wu Huijuan, Hong Zhao, Wei Liu, Zheng Xiang*, Qi Wang(王琦)*. Apigenin, a flavonoidconstituent derived from P. villosa, inhibits hepatocellular carcinoma cellgrowth by CyclinD1/CDK4 regulation via p38 MAPK-p21 signaling. Pathology-Researchand Practice. 2020,216(1):152701.

10)   Qi Wang(王琦), Curt Hagedorn*,Shuanghu Liu*. Adapted HCV JFH1 variant is capable of accommodating a largeforeign gene insert and allows lower level HCV replication and viralproduction. International Journal of Biological Sciences. 2018,14:1211-1220.

11) Qi Wang(王琦)#, Yue Li#,Shun-Ai Liu, Wen Xie, Jun Cheng. Cell culture-adaptive mutations in hepatitis Cvirus promote viral production by enhancing viral replication and release. WorldJournal of Gastroenterology. 2018, 24(12):1299-1311.

12) Qi Wang(王琦), Hongbo Du, MinLi, Yue Li, Shunai Liu, Ping Gao, Xiaoli Zhang, Jun Cheng. MAPK signaltransduction pathway regulation: A novel mechanism of rat HSC-T6 cell apoptosisinduced by FUZHENGHUAYU Tablet. Evidence-based Complementary and AlternativeMedicine. 2013(2013), 368103.

13) Qi Wang(王琦)#, YongshengWang#, Yue Li, Xuesong Gao, Shunai Liu, Jun Cheng. NS5ATP9 contributes toinhibition of cell proliferation by hepatitis C virus (HCV) nonstructuralprotein 5A (NS5A) via MEK/Extracellular signal regulated kinase (ERK) pathway. InternationalJournal of Molecular Sciences. 2013, 14(5), 10539- 10551.

14) Hao Song#, Qi Wang(王琦)#, Yang Guo#, Shunai Liu, Rui Song,Xuesong Gao, Li Dai, Baoshun Li, Deli Zhang*, Jun Cheng*.Microarray analysis ofmicroRNA expression in peripheral blood mononuclear cells of critically ill patientswith influenza A (H1N1). BMC Infectious Diseases. 2013,13:257.

15)Hao Song#, Qi Wang(王琦)#, Junge Wen, Shunai Liu, XuesongGao, Jun Cheng*, Deli Zhang*. ACVR1, a therapeutic target of fibrodysplasiaossificans progressiva, is negatively regulated by miR-148a. InternaltionalJournal of Molecular Sciences. 2012, 13(2):2063-2077.

省/部级奖励：

1)  中共河北省委/河北省人民政府/北京冬奥组委：北京冬奥会、冬残奥会河北省先进个人（2022.04.19）

2)   国家体育总局冬运中心：“中国冰雪之夜”耕耘荣誉

3)  中共北京市委/市政府：北京市抗击新冠疫情先进个人（2020.09.30）

4)  教育部：2012年度国家奖学金

局级奖励：

1)  北京大学医学部教育处、北京大学医学部传染病学系：2020-2021年度北京大学医学部传染病学系赵树馨教授奖励基金